clinical Trials

• Tyligand Bioscience Announces First Patient Dosed for the Phase 1 Trial of TSN222，the Global First Dual Action Tumor Immune Agonist
• Tyligand Bioscience Announces First Patient Dosed in Phase 1/2 Clinical Trial of TSN1611, a Selective and Orally Bioavailable KRAS G12D Inhibitor
• Tyligand Bioscience Presents Latest Clinical Data of KRAS G12D Inhibitor TSN1611 at the 2026 ASCO GI
• Tyligand Bioscience Presents Preclinical Data on FDA IND-Cleared KRAS G12D Inhibitor TSN1611 at the 2024 AACR Annual Meeting
• Tyligand Bioscience Receives Clinical Trial Clearance from U.S. FDA and China NMPA for Dual Function Immune Agonist TSN222
• Tyligand Bioscience's KRAS G12D Inhibitor TSN1611 Selected for 2026 ASCO Rapid Oral Abstract Session